The molecular classification of muscle-invasive urothelial cancer (UC) using RNA sequencing (RNAseq) data has confirmed the existence of distinct intrinsic subtypes that vary in their prognosis and response to therapy. The molecular classifier BASE47 (Bladder cancer Analysis of Subtype by gene Expression) uses RNAseq transcriptomic data to differentiate between basal-like and luminal-like subtypes. Although the BASE47 gene expression profiling data could guide clinical decisions, the routine use of these platforms is restricted by cost and technical difficulties.